睿知中国医院研究地图
候选清单

即将招募胰腺癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Comparing Astragalus Plus Gemcitabine to Gemcitabine Alone as Neoadjuvant Treatment for Pancreatic Cancer Patients

ClinicalTrials.gov 上登记的一项胰腺癌开放试验,由深圳大学总医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方深圳大学总医院Shenzhen University General Hospital深圳医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06234072,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 6

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(6 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Histologically or cytologically confirmed diagnosis of pancreatic ductal adenocarcinoma;

    入选标准第 1 条

  3. Past or concurrent cancers with primary foci or histology completely different from pancreatic cancer, except for cervical cancer in situ, previously treated basal cell carcinoma, and superficial bladder tumors (Ta, Tis \& T1). Any cancer cured >5 years prior to enrollment is allowed;

    排除标准第 8 条

  4. Pregnant or lactating women. Women of childbearing potential who are unwilling or unable to use an acceptable method of contraception throughout the treatment period of this trial and for 12 weeks after the last dose of study drug. Sexually active, fertile men who are not using effective contraception themselves if their partner is a woman of childbearing potential;

    排除标准第 5 条

  5. ECOG performance status 0 to 2;

    入选标准第 3 条

  6. Neutrophils 1,500/Ul,

    入选标准第 6 条

    hemoglobin > 8.0 gm/dL,

    入选标准第 7 条

    Platelet count ≥ 100,000/mm3 (IU: ≥ 100 x 109/L),

    入选标准第 8 条

    serum creatinine < 2.0 mg/dL,

    入选标准第 9 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:影像与可测量病灶;试验排除的其他疾病;怀孕、哺乳与避孕。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06234072,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Histologically or cytologically confirmed diagnosis of pancreatic ductal adenocarcinoma;
  2. Is 18 years of age or older;
  3. ECOG performance status 0 to 2;
  4. Transaminases AST (SGOT) and ALT (SGPT) ≤ 2.5 times the upper limit of normal (ULN). If liver function abnormalities are due to underlying liver metastasis, then AST (SGOT) and ALT (SGPT) may be ≤ 5 times ULN.
  5. Total serum bilirubin ≤ 3.0 times ULN (if due to underlying liver metastasis, then total bilirubin may be ≤ 5 times ULN),
  6. Neutrophils 1,500/Ul,
  7. hemoglobin > 8.0 gm/dL,
  8. Platelet count ≥ 100,000/mm3 (IU: ≥ 100 x 109/L),
  9. serum creatinine < 2.0 mg/dL,
  10. Expected postoperative survival ≥ 3 months;
  11. Ability to comply with the study visit plan and other protocol requirements;
  12. Voluntary participation and signing of informed consent.
  13. Is willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

排除标准:Exclusion Criteria:

  1. CNS damage or soft meningeal disease;
  2. Metastasis to distant sites;
  3. Other serious diseases or conditions, including congestive heart failure (New York Heart Association class III or IV), unstable angina pectoris, infarction in the past 6 months, severe arrhythmia, prolonged QT interval, active HIV infection or HIV disease, mental disorders, and substance abuse;
  4. Known hypersensitivity to Astragalus or gemcitabine;
  5. Pregnant or lactating women. Women of childbearing potential who are unwilling or unable to use an acceptable method of contraception throughout the treatment period of this trial and for 12 weeks after the last dose of study drug. Sexually active, fertile men who are not using effective contraception themselves if their partner is a woman of childbearing potential;
  6. Known neuroendocrine tumor of the pancreas;
  7. Receiving a concomitant treatment with drugs interacting with gemcitabine;
  8. Past or concurrent cancers with primary foci or histology completely different from pancreatic cancer, except for cervical cancer in situ, previously treated basal cell carcinoma, and superficial bladder tumors (Ta, Tis \& T1). Any cancer cured >5 years prior to enrollment is allowed;
  9. Inability to swallow herbal medicines or untreated malabsorption syndrome and unwillingness to take herbal medicines.
  10. Patients with poor compliance

引自 ClinicalTrials.gov, NCT06234072, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06234072,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06234072